Table 1 Baseline demographic and disease characteristics

Age (years), median (IQR)

9.0 (4.7–12.9)

10.2 (6.6–13.9)

8.6 (4.2–12.4)

Symptom duration (mo.), median (IQR)

8.1 (5.5–11.9)

5.9 (4.6–13.3)

8.6 (5.2–13.4)

ANA pos, n (%)

14 (45.2)

11 (34.4)

9 (31.0)

Female, n (%)

23 (74.2)

19 (59.4)

19 (65.5)

JIA Category

    Oligo, n(%)

5 (16.1)

3 (9.4)

3 (10.3)

    Oligoarticular < 6 months

1

1

3

    Oligoarticular >  = 6 months

4 (12.9)

2 (6.3)

0

    Poly, n (%)

24 (77.4)

25 (78.1)

24 (82.8)

    Psoriatic, n (%)

2 (6.4)

4 (12.5)

2 (6.9)

PGA mean (SD) in mm

46.4 ± 15.4

49.7 ± 16.1

51.2 ± 16.6

VAS patient/parent general well-being, mean (SD) in mm

48.9 ± 21.9

56.3 ± 21.4

54.6 ± 22.6

VAS pain mean (SD) in mm

54.7 ± 20.0

54.5 ± 23.0

56.8 ± 22.7

CHAQ, mean (SD)

0.9 ± 0.7

1.1 ± 0.6

1.1 ± 0.5

CHQ-PF50

    CHQ-PhS, mean (SD)

32.0 ± 13.4

30.1 ± 12.4

31.0 ± 12.2

    CHQ-PsS, mean (SD)

45.4 ± 12.4

46.0 ± 10.5

47.7 ± 9.1

No. active joints, median (IQR)

7.0 (5.0–13.0)

7.5 (6.0–11.8)

8.0 (5.5–13.0)

No. limited joints, median (IQR)

2.0 (0–3.0)

2.0 (1.0–3.8)

3.0 (1.5–5.0)

ESR, median (IQR)

6.0 (2.0–11.0)

6.0 (2.0–23.5)

9.0 (3.5–26.0)

JADAS-10, mean (SD)

16.5 ± 4.2

18.8 ± 4.4

18.8 ± 5.4

NSAID use, n (%)

26 (83.9)

27 (84.4)

25 (86.2)